236 related articles for article (PubMed ID: 33803981)
21. [Involvement of aberrant DNA methylation in hematological malignancies].
Matsui H
Rinsho Ketsueki; 2014 Oct; 55(10):1709-14. PubMed ID: 25297731
[No Abstract] [Full Text] [Related]
22. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
[TBL] [Abstract][Full Text] [Related]
23. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
24. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Tefferi A; Levine RL; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Finke CM; Mullally A; Li CY; Pardanani A; Gilliland DG
Leukemia; 2009 May; 23(5):900-4. PubMed ID: 19262599
[TBL] [Abstract][Full Text] [Related]
25.
Leoni C; Montagner S; Rinaldi A; Bertoni F; Polletti S; Balestrieri C; Monticelli S
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1490-E1499. PubMed ID: 28167789
[TBL] [Abstract][Full Text] [Related]
26. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.
Stoecker MM; Wang E
Arch Pathol Lab Med; 2012 Jul; 136(7):832-8. PubMed ID: 22742558
[TBL] [Abstract][Full Text] [Related]
27. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic modifiers in normal and malignant hematopoiesis.
Haladyna JN; Yamauchi T; Neff T; Bernt KM
Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
[TBL] [Abstract][Full Text] [Related]
30. The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
[TBL] [Abstract][Full Text] [Related]
31. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
32. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
Wakita S; Yamaguchi H
Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
[TBL] [Abstract][Full Text] [Related]
33. A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases.
Grifoni FI; Sciumè M; Pravettoni V; Ulivieri FM; Muratori S; Fracchiolla NS; Tagliaferri E; Gianelli U; Migliorini AC; Cro L; Pacilli A; Mannelli F; Baldini L
Hematol Oncol; 2019 Apr; 37(2):205-211. PubMed ID: 30849188
[TBL] [Abstract][Full Text] [Related]
34. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
35. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
36. [Clonal haematopoiesis: A concise review].
Danlos FX; Papo M; Micol JB
Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
[TBL] [Abstract][Full Text] [Related]
37. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
39. Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.
Molderings GJ
Transl Res; 2016 Aug; 174():86-97. PubMed ID: 26880691
[TBL] [Abstract][Full Text] [Related]
40. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
